Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202

EXTON, Pa., Jan. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) Application for MORAb-202,... Biopharmaceuticals, Oncology, FDA Morphotek, Eisai, Farletuzumab, eribulin

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043383

Source: HSMN NewsFeed - January 10, 2018 Category: Pharmaceuticals Source Type: news